The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript
The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript January 8, 2026 The Simply Good Foods Company beats earnings expectations. Reported EPS is $0.39, expectations were $0.36. Operator: Greetings. Welcome to Simply Good Foods Company’s First Quarter Fiscal Year 2026 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. At this […]
Prescryptive and Ilant Health Expand Employer-Direct Access to Obesity Care and Transparent GLP-1 Access at Scale
REDMOND, Wash., Jan. 9, 2026 /PRNewswire/ — Prescryptive and Ilant Health today announced a collaboration to help employers access transparent GLP-1 pricing alongside expert, outcomes-driven clinical care. The collaboration runs on Prescryptive’s direct-to-market platform, aligned by…
Weight-loss experts predict 5 major treatment changes likely to emerge in 2026
Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods. Weight-loss experts spoke with Fox News Digital about their predictions for the most major changes to come in 2026. Dr. Peter Balazs, a hormone and weight loss specialist in New York and New […]
Amazon pharmacy now offers Novo Nordisk’s oral GLP-1 weight loss pill
STAT+: Pharmalittle: We’re reading about a potential Merck purchase, a J&J pricing deal with Trump, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, promenade with the official mascots, and hope to hold still […]
Pharmaceutics, Vol. 18, Pages 86: The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
Pharmaceutics, Vol. 18, Pages 86: The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis Pharmaceutics doi: 10.3390/pharmaceutics18010086 Authors: Denisia Adelina Tornea Christian Goldis Alexandru Isaic Alexandru Catalin Motofelea Alexandra Christa Sima Tudor Ciocarlie Andreea Crintea Razvan Gheorghe Diaconescu Nadica Motofelea Adrian Goldis Background: Metabolically associated fatty liver […]
Weighing the Good and Bad of Weight-Loss Drugs
Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes treatments to blockbuster weight-loss medications. But is the hype backed up by science? In this episode, freelance science journalist Bethany Brookshire joins host Kendra Pierre-Louis to talk about how these drugs mimic natural hormones, why they’re so effective […]
Food pyramid faces scrutiny as Ben Carson reveals why Americans don’t have to eat meat
The new food pyramid has been flipped on its head, with HHS officials releasing guidance that prioritizes meat, dairy and vegetables and pushes whole grains to the bottom. Dr. Ben Carson, USDA’s national advisor for nutrition, health and housing, told Fox News Digital that dietary guidelines were first proposed in 1980 to inform Americans about […]
The Weight-Loss Drug Revolution—From Shots to Pills and the Science behind It All
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
GLP1‐1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta‐analysis of randomised controlled trials and cohort studies
Abstract Aims The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of major adverse limb events (MALE) or lower extremity amputation (LEA) in people with type 2 diabetes and peripheral artery disease (PAD). Materials and Methods We searched many electronic databases up […]